vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). Tecnoglass Inc. runs the higher net margin — 10.6% vs -0.7%, a 11.4% gap on every dollar of revenue. On growth, Tecnoglass Inc. posted the faster year-over-year revenue change (2.4% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $11.4M). Over the past eight quarters, Tecnoglass Inc.'s revenue compounded faster (12.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
AVNS vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $245.3M |
| Net Profit | $-1.3M | $26.1M |
| Gross Margin | 47.5% | 40.0% |
| Operating Margin | 1.4% | 18.3% |
| Net Margin | -0.7% | 10.6% |
| Revenue YoY | 0.7% | 2.4% |
| Net Profit YoY | 99.7% | -44.5% |
| EPS (diluted) | $-0.02 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $245.3M | ||
| Q3 25 | $177.8M | $260.5M | ||
| Q2 25 | $175.0M | $255.5M | ||
| Q1 25 | $167.5M | $222.3M | ||
| Q4 24 | $179.6M | $239.6M | ||
| Q3 24 | $170.4M | $238.3M | ||
| Q2 24 | $171.7M | $219.7M | ||
| Q1 24 | $166.1M | $192.6M |
| Q4 25 | $-1.3M | $26.1M | ||
| Q3 25 | $-1.4M | $47.2M | ||
| Q2 25 | $-76.8M | $44.1M | ||
| Q1 25 | $6.6M | $42.2M | ||
| Q4 24 | $-397.3M | $47.0M | ||
| Q3 24 | $4.3M | $49.5M | ||
| Q2 24 | $1.8M | $35.0M | ||
| Q1 24 | $-900.0K | $29.7M |
| Q4 25 | 47.5% | 40.0% | ||
| Q3 25 | 48.4% | 42.7% | ||
| Q2 25 | 52.6% | 44.7% | ||
| Q1 25 | 53.6% | 43.9% | ||
| Q4 24 | 54.6% | 44.5% | ||
| Q3 24 | 54.5% | 45.8% | ||
| Q2 24 | 55.7% | 40.8% | ||
| Q1 24 | 57.1% | 38.8% |
| Q4 25 | 1.4% | 18.3% | ||
| Q3 25 | 0.1% | 25.1% | ||
| Q2 25 | -42.6% | 24.0% | ||
| Q1 25 | 6.1% | 26.7% | ||
| Q4 24 | -233.0% | 28.0% | ||
| Q3 24 | 7.0% | 28.4% | ||
| Q2 24 | 3.7% | 23.3% | ||
| Q1 24 | 2.4% | 21.3% |
| Q4 25 | -0.7% | 10.6% | ||
| Q3 25 | -0.8% | 18.1% | ||
| Q2 25 | -43.9% | 17.3% | ||
| Q1 25 | 3.9% | 19.0% | ||
| Q4 24 | -221.2% | 19.6% | ||
| Q3 24 | 2.5% | 20.8% | ||
| Q2 24 | 1.0% | 15.9% | ||
| Q1 24 | -0.5% | 15.4% |
| Q4 25 | $-0.02 | $0.57 | ||
| Q3 25 | $-0.03 | $1.01 | ||
| Q2 25 | $-1.66 | $0.94 | ||
| Q1 25 | $0.14 | $0.90 | ||
| Q4 24 | $-8.64 | $1.00 | ||
| Q3 24 | $0.09 | $1.05 | ||
| Q2 24 | $0.04 | $0.75 | ||
| Q1 24 | $-0.02 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $104.1M |
| Total DebtLower is stronger | $90.3M | $174.4M |
| Stockholders' EquityBook value | $778.2M | $713.1M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $104.1M | ||
| Q3 25 | $70.5M | $127.1M | ||
| Q2 25 | $90.3M | $140.9M | ||
| Q1 25 | $97.0M | $160.2M | ||
| Q4 24 | $107.7M | $137.5M | ||
| Q3 24 | $89.0M | $124.8M | ||
| Q2 24 | $92.2M | $129.5M | ||
| Q1 24 | $75.8M | $138.8M |
| Q4 25 | $90.3M | $174.4M | ||
| Q3 25 | $93.4M | $114.7M | ||
| Q2 25 | $95.7M | $110.6M | ||
| Q1 25 | $98.0M | $110.6M | ||
| Q4 24 | $125.3M | $111.1M | ||
| Q3 24 | $152.6M | $126.8M | ||
| Q2 24 | $164.9M | $144.7M | ||
| Q1 24 | $167.2M | $160.9M |
| Q4 25 | $778.2M | $713.1M | ||
| Q3 25 | $778.0M | $764.0M | ||
| Q2 25 | $776.3M | $736.0M | ||
| Q1 25 | $839.4M | $685.1M | ||
| Q4 24 | $828.5M | $631.2M | ||
| Q3 24 | $1.2B | $613.3M | ||
| Q2 24 | $1.2B | $574.8M | ||
| Q1 24 | $1.2B | $573.6M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.7B | $996.3M | ||
| Q2 24 | $1.7B | $942.5M | ||
| Q1 24 | $1.7B | $981.6M |
| Q4 25 | 0.12× | 0.24× | ||
| Q3 25 | 0.12× | 0.15× | ||
| Q2 25 | 0.12× | 0.15× | ||
| Q1 25 | 0.12× | 0.16× | ||
| Q4 24 | 0.15× | 0.18× | ||
| Q3 24 | 0.12× | 0.21× | ||
| Q2 24 | 0.13× | 0.25× | ||
| Q1 24 | 0.14× | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $31.0M |
| Free Cash FlowOCF − Capex | $21.3M | $11.4M |
| FCF MarginFCF / Revenue | 11.8% | 4.7% |
| Capex IntensityCapex / Revenue | 3.8% | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $31.0M | ||
| Q3 25 | $14.0M | $40.0M | ||
| Q2 25 | $6.8M | $17.9M | ||
| Q1 25 | $25.7M | $46.9M | ||
| Q4 24 | $57.9M | $61.1M | ||
| Q3 24 | $23.0M | $41.5M | ||
| Q2 24 | $27.8M | $34.5M | ||
| Q1 24 | $-8.0M | $33.4M |
| Q4 25 | $21.3M | $11.4M | ||
| Q3 25 | $7.0M | $21.2M | ||
| Q2 25 | $-4.2M | $-14.7M | ||
| Q1 25 | $19.0M | $16.5M | ||
| Q4 24 | $53.1M | $35.4M | ||
| Q3 24 | $20.0M | $17.8M | ||
| Q2 24 | $21.9M | $14.2M | ||
| Q1 24 | $-12.1M | $23.6M |
| Q4 25 | 11.8% | 4.7% | ||
| Q3 25 | 3.9% | 8.2% | ||
| Q2 25 | -2.4% | -5.7% | ||
| Q1 25 | 11.3% | 7.4% | ||
| Q4 24 | 29.6% | 14.8% | ||
| Q3 24 | 11.7% | 7.5% | ||
| Q2 24 | 12.8% | 6.5% | ||
| Q1 24 | -7.3% | 12.2% |
| Q4 25 | 3.8% | 8.0% | ||
| Q3 25 | 3.9% | 7.2% | ||
| Q2 25 | 6.3% | 12.7% | ||
| Q1 25 | 4.0% | 13.7% | ||
| Q4 24 | 2.7% | 10.7% | ||
| Q3 24 | 1.8% | 9.9% | ||
| Q2 24 | 3.4% | 9.2% | ||
| Q1 24 | 2.5% | 5.1% |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | 3.89× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | 5.35× | 0.84× | ||
| Q2 24 | 15.44× | 0.98× | ||
| Q1 24 | — | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
